ForeverGreen on Pace to Have a Banner Year

Demonstrating remarkable demand and heavy interest in its products, ForeverGreen has beaten the odds by reporting tremendous year-over-year revenue growth for the month of January 2014. Considering that ForeverGreen is generating the industry’s greatest top-line growth rates and trades at a low relative P/E multiple, it is likely that the stock begins to arrive on many investors’ radar screens this quarter.

Read more...
 
Raising Global Payout Price Target
Global Payout (OTC:GOHE) has been one of the best performers in the OTC market space. In recent months, rising 420% since our last report in September. We are substantially raising our price target due in response to an amazing series of new contract awards in just a matter of weeks, with more to come, along with profitability in 1H14 as well.
Read more...
 
More Good News Should Propel Stock Higher
One of the biggest hurdles in the medical marijuana and recreational marijuana industries is changing for the better which, when finalized, will have a profoundly positive impact on MediSwipe.
Read more...
 
A New Medical Marijuana Play

MediSwipe, which helped pioneer and design the use of a HIPAA-compliant back end record system, is the only pure play medical marijuana stock with a real presence in the critical payments and records segment of the industry. With its peers trading at an average market cap north of $200M, the overlooked MWIP has not yet made the big, inevitable run higher and could easily trade up to $1.00 in the near term.

Read more...
 
The Best Way to Play Online Deals

Today we are issuing a new research report on LiveDeal (NASDAQ – LIVE). LIVE’s shares split 3 for 1 as of the open today and that usually means a big increase in trading from Day One. LIVE is transforming the online deal space and is eating Groupon’s lunch. See why we think the stock more than doubles to $12 this year and then doubles again to $24 in 2015.

Read more...
 
LiveDeal Undervalued Compared to Peers

As the new kid on the block, LIVE is making waves in the daily deal space that Wall Street has really taken notice of since the first of the year, sending shares upwards by about 550 percent at a January high of $25.73.

Read more...
 
Plandaí Sits at the Head of the Medical Marijuana Class

With the announcement of its recent license agreement with Diego Pellicer, Inc. and Diego Pellicer Worldwide Inc., Plandaí Biotechnology, Inc. (OTCQB –PLPL - $0.49 – Spec Buy) has positioned itself at the head of the class in the medical marijuana industry. The license enables Plandaí to use the Diego Pellicer name for its Phytofare™ cannabis extracts in medical and pharmaceutical marijuana applications.

Read more...
 
NVLX: Upcoming Catalysts to Drive NVLX to Highs

A series of recent landmark events in the marijuana and medical marijuana space, along with a revaluation of biotechs, are set to serve as triggers prompting the accumulation and rise of Nuvilex’s stock back to the levels enjoyed roughly 9 months ago.

Read more...
 
ForeverGreen’s PowerStrips Could Be a Game-Changer

Given that sales of PowerStrips alone approached $12 million in 2013 during the pre-launch phase, it is easy to see why sales are expected to escalate substantially in 2014. Moreover, since ForeverGreen management has recently provided Wall Street with monthly sales updates, investors can monitor overall progress and sales success rates, thus providing a healthy dose of comfort in the stock’s future, just like PowerStrips themselves.

Read more...
 
New Product Could Displace Skype
ChitChatr Communications is set to launch a new and innovative, integrated platform that could emerge as a new standard bearer for users across the globe. The Company is delivering this unified application through the fast-growing, low cost and highly effective VoIP technology. For example, the growth in mobile VoIP minutes is expected to leap from 15 billion in 2010 to 470 billion in 2015. In our view, CHICF could ultimately be worth hundreds of millions since the ChitrChatr UUCP will offer competitive long term advantages that could lead to the displacement of current, non-app integrated popular tools such as Skype or Whatsapp which have at one time or another been valued at over $1 billion. As new users are signed up and development milestones are reached, we believe the stock will be driven toward our $3.75 price target. We rate these shares Speculative Buy.
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 19 of 41